KR20190068602A - 항-kir3dl2 작용제에 의한 치료 - Google Patents

항-kir3dl2 작용제에 의한 치료 Download PDF

Info

Publication number
KR20190068602A
KR20190068602A KR1020197014069A KR20197014069A KR20190068602A KR 20190068602 A KR20190068602 A KR 20190068602A KR 1020197014069 A KR1020197014069 A KR 1020197014069A KR 20197014069 A KR20197014069 A KR 20197014069A KR 20190068602 A KR20190068602 A KR 20190068602A
Authority
KR
South Korea
Prior art keywords
kir3dl2
antibody
ser
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197014069A
Other languages
English (en)
Korean (ko)
Inventor
까린 파뛰렐
엘렌 시까르
Original Assignee
이나뜨 파르마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이나뜨 파르마 filed Critical 이나뜨 파르마
Priority to KR1020237043171A priority Critical patent/KR20230173745A/ko
Publication of KR20190068602A publication Critical patent/KR20190068602A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061Blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020197014069A 2016-10-21 2017-10-19 항-kir3dl2 작용제에 의한 치료 Ceased KR20190068602A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237043171A KR20230173745A (ko) 2016-10-21 2017-10-19 항-kir3dl2 작용제에 의한 치료

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410880P 2016-10-21 2016-10-21
US62/410,880 2016-10-21
PCT/EP2017/076751 WO2018073363A1 (en) 2016-10-21 2017-10-19 Treatment with anti-kir3dl2 agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237043171A Division KR20230173745A (ko) 2016-10-21 2017-10-19 항-kir3dl2 작용제에 의한 치료

Publications (1)

Publication Number Publication Date
KR20190068602A true KR20190068602A (ko) 2019-06-18

Family

ID=60268349

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197014069A Ceased KR20190068602A (ko) 2016-10-21 2017-10-19 항-kir3dl2 작용제에 의한 치료
KR1020237043171A Pending KR20230173745A (ko) 2016-10-21 2017-10-19 항-kir3dl2 작용제에 의한 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237043171A Pending KR20230173745A (ko) 2016-10-21 2017-10-19 항-kir3dl2 작용제에 의한 치료

Country Status (8)

Country Link
US (3) US20190248895A1 (enExample)
EP (1) EP3529277A1 (enExample)
JP (1) JP7676109B2 (enExample)
KR (2) KR20190068602A (enExample)
CN (1) CN109863175A (enExample)
AU (1) AU2017345203B2 (enExample)
CA (1) CA3037851A1 (enExample)
WO (1) WO2018073363A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881765C (en) 2012-09-19 2024-02-13 Innate Pharma Kir3dl2 binding agents
ES2878749T3 (es) 2013-02-20 2021-11-19 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
CN106132989B (zh) 2014-03-14 2020-06-19 先天制药公司 具有增加的稳定性的人源化抗体
BR112021014236A2 (pt) * 2019-01-22 2021-09-28 Innate Pharma Anticorpo, composição farmacêutica, kit e método para predizer ou avaliar a eficácia

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
JP2004528824A (ja) 2000-12-18 2004-09-24 アーンスティテュ ナシオナール ド ラ サント エ ド ラ ルシェルシェ メディカル(イー.エンヌ.エス.ウー.エール.エンム.) 皮膚t細胞リンパ腫(ctcl)の新規な診断及び治療法
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CN1930288B (zh) 2002-04-09 2012-08-08 协和发酵麒麟株式会社 基因组被修饰的细胞
US20050260213A1 (en) 2004-04-16 2005-11-24 Scott Koenig Fcgamma-RIIB-specific antibodies and methods of use thereof
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス,インコーポレーテッド FcγRIIB特異的抗体とその利用法
JP2004126818A (ja) 2002-09-30 2004-04-22 Toshiba Corp 電子機器システム、電池ユニットおよび電池ユニットの動作制御方法
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US20090191213A9 (en) 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
KR20060079180A (ko) 2003-07-02 2006-07-05 노보 노르디스크 에이/에스 Nk 세포 활성을 조절하기 위한 조성물 및 방법
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
JP2008502322A (ja) 2004-04-30 2008-01-31 イネイト・ファーマ Nk細胞活性を高めるための組成物および方法
CA2565874C (en) 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
DK2287195T3 (da) 2004-07-01 2019-08-19 Innate Pharma Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
DK2412728T3 (en) 2004-08-03 2015-04-07 Innate Pharma Therapeutic compositions for cancer, that target 4Ig-B7-H3
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
PL1836225T3 (pl) 2005-01-06 2012-05-31 Novo Nordisk As Czynniki wiążące kir i sposoby ich stosowania
KR20080032065A (ko) 2005-06-03 2008-04-14 제넨테크, 인크. 푸코실화 수준이 조절된 항체의 생성 방법
PL1919503T3 (pl) 2005-08-10 2015-04-30 Macrogenics Inc Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
FR2894982A1 (fr) 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
WO2007084922A2 (en) 2006-01-17 2007-07-26 Biolex Therapeutics, Inc. Compositions and methods for humanization and optimization of n-glycans in plants
JP2009529331A (ja) 2006-03-10 2009-08-20 マクロジェニクス,インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
CA2660592C (en) 2006-05-26 2016-07-12 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
EP2379598B1 (en) 2009-01-19 2015-03-11 Innate Pharma Anti-kir3d antibodies
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
WO2012175613A1 (en) 2011-06-21 2012-12-27 Innate Pharma NKp46-MEDIATED NK CELL TUNING
CA2881765C (en) 2012-09-19 2024-02-13 Innate Pharma Kir3dl2 binding agents
EP2897979B1 (en) 2012-09-19 2019-02-13 Innate Pharma Kir3dl2 binding agents
DK3255062T3 (da) 2013-02-14 2019-10-07 Innate Pharma Anti-nkp46-antistof til diagnosticering af et ikke-kutant perifert t-cellelymfom (ptcl)
ES2878749T3 (es) 2013-02-20 2021-11-19 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
CN106132989B (zh) 2014-03-14 2020-06-19 先天制药公司 具有增加的稳定性的人源化抗体
WO2016030488A1 (en) * 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
SG11201701387SA (en) 2014-09-16 2017-03-30 Innate Pharma Treatment regimens using anti-nkg2a antibodies
CA2990518A1 (en) 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins

Also Published As

Publication number Publication date
US11970535B2 (en) 2024-04-30
KR20230173745A (ko) 2023-12-27
US20240391999A1 (en) 2024-11-28
EP3529277A1 (en) 2019-08-28
CN109863175A (zh) 2019-06-07
US20190248895A1 (en) 2019-08-15
JP7676109B2 (ja) 2025-05-14
AU2017345203A1 (en) 2019-05-02
JP2020500161A (ja) 2020-01-09
AU2017345203B2 (en) 2024-08-01
CA3037851A1 (en) 2018-04-26
US20210087270A1 (en) 2021-03-25
WO2018073363A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
US20240124579A1 (en) Kir3dl2 binding agents
JP6847037B2 (ja) 抗cd73抗体とa2a受容体阻害薬とを含む併用治療薬及びその使用
AU2013218017B2 (en) MICA binding agents
CN107670034B (zh) FcγRIIB(CD32B)和CD20特异性抗体的组合应用
AU2014220668B2 (en) A compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
US20240391999A1 (en) Treatment with anti-kir3dl2 agents
KR20170054442A (ko) 항-cd38 항체를 사용하는 병용 요법
US20170198040A1 (en) ANTIBODIES TARGETING CD32b AND METHODS OF USE THEREOF
JP2022516140A (ja) 白血球免疫グロブリン様受容体2中和抗体
KR20210119454A (ko) T 세포 림프종의 치료
WO2016030488A1 (en) Treatment of celiac disease
HK40067401A (en) Combined use of fcγriib(cd32b) and cd20 specific antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190516

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201013

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221027

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230719

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20221027

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20231213

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20230719

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2023101002683

Request date: 20231213

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101002683; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20231213

Effective date: 20240730

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20240730

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20231213

Decision date: 20240730

Appeal identifier: 2023101002683

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20240912

WITB Written withdrawal of application
J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20240913

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2023101002683

Request date: 20231213

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20240730